Analysis of risk factors for postoperative complications in non-small cell lung cancer: comparison with the Japanese National Clinical Database risk calculator

Nozomu Motono*, Masahito Ishikawa, Shun Iwai, Aika Yamagata, Yoshihito Iijima and Hidetaka Uramoto

Abstract
Background: Although the risk calculator of the National Clinical Database (RC-NCD) has been widely used to predict the occurrence of mortality and major morbidity in Japan, it has not been demonstrated whether a correlation between the calculated RC-NCD risk score and the actual occurrence of mortality and severe morbidity exists.

Methods: The clinical data of 585 patients who underwent pulmonary resection for non-small cell lung cancer were collected, and the risk factors for postoperative morbidity were analyzed to verify the validity of the RC-NCD.

Results: The coexistence of asthma ($p = 0.02$), nutrition lymphocyte ratio ($p = 0.04$), and pulmonary lobe ($p < 0.01$) were significant risk factors for postoperative morbidity in the present study, and the percent-predicted vital capacity ($p < 0.01$), pulmonary lobe ($p = 0.03$), and type of operative procedure ($p = 0.01$) were significant risk factors for severe postoperative morbidity. Furthermore, in patients received lobectomy, coexistence of asthma ($p = 0.01$) and pulmonary lobe ($p < 0.01$) were identified as significant risk factors for postoperative morbidity. Meanwhile, male sex ($p = 0.01$), high BMI ($p < 0.01$), low vital capacity ($p = 0.04$), and pulmonary lobe ($p = 0.03$) were identified as significant risk factors for severe postoperative morbidity.

Conclusions: Given that the pulmonary lobe was a significant risk factor for postoperative morbidity in patients received pulmonary resection and for severe postoperative morbidity in patients received lobectomy, the RC-NCD for postoperative morbidity needs to be modified according to high-risk lobes.

Trial registration: The Institutional Review Board of Kanazawa Medical University approved the protocol of this retrospective study (approval number: I392), and written informed consent was obtained from all patients.

Keywords: Postoperative complication, Risk factor, Non-small cell lung cancer

Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide [1]. The incidence of postoperative complications associated with pulmonary resection for non-small cell lung cancer (NSCLC) has been reported to be 9–37% [2–4]. Furthermore, the incidence of postoperative complications associated with lobectomy is 10–50% and has been observed to be higher in the elderly than in younger individuals [5]. Several postoperative complications can occur after pulmonary resection, commonly including air leakage, pneumonia, atelectasis, and arrhythmia. The incidence of postoperative pulmonary complications after pulmonary resection has been reported to be 6–30% [6–10]. Age, smoking history, and...
chronic obstructive pulmonary disease (COPD) are considered significant risk factors for postoperative pulmonary complications.

In 2011, the National Clinical Database (NCD) of Japan began an annual web-based data collection registration system. Data on 1.6 million surgical procedures from more than 4,000 hospitals were collected [11]. The risk calculator system was established based on a model of lung cancer surgery risk derived from the NCD of 78,594 patients from the years 2014 to 2015 [12]. In this study, mortality and the combination of mortality and major morbidity were analyzed. Operative mortality was defined as death within 30 days after surgery, and major morbidity was defined according to the Society of Thoracic Surgeons General Thoracic Database (STS GTDB) [13, 14]. Although the risk calculator of NCD (RC-NCD) has been widely used to predict the occurrence of mortality and major morbidity in Japan (Fig. 1), whether or not there is a correlation between the risk score calculated by the RC-NCD and the actual occurrence of mortality and severe morbidity has not been demonstrated.

In the present study, we retrospectively evaluated the risk factors for mortality and morbidity after pulmonary resection in patients with NSCLC and verified the validity of the RC-NCD.

**Materials and methods**

**Patients**

Seven hundred and thirty-nine NSCLC patients were received pulmonary resection at Kanazawa Medical University between January 2010 and March 2019, and 154 patients who underwent wedge resection were excluded. Therefore, 585 patients were enrolled in this retrospective study (Fig. 2).

Data including clinical factors, such as the sex, age, comorbidities, smoking history, body mass index (BMI), carcinoembryonic antigen (CEA) levels, respiratory function, prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), tumor diameter on computed tomography (CT), lobe involvement in lung cancer, clinical and pathological stage, and histology, were collected. The following comorbidities were included, according to the factors of the RC-NCD: malignant disease, hypertension, diabetes mellitus, angina pectoris, COPD, cerebral infarction, arrhythmia, interstitial lung disease, asthma, autoimmune disease, and chronic renal failure. Respiratory function parameters, such as the percent-predicted vital capacity (%VC) and forced expiratory volume in 1 s as a percentage of forced vital capacity (FEV₁), were collected. The PNI, calculated from the serum albumin level and total lymphocyte count, is a simple and useful indicator of one’s immune-nutritional status [15]. The NLR was defined as the ratio of the neutrophil to the lymphocyte count, functioning as a parameter of systemic inflammation and stress in critically ill surgical and medical patients [16]. The smoking history was assessed using the Brinkman index, which is calculated by multiplying the number of cigarettes smoked per day by the number of years the subject has been smoking [17].

**Operative factors**

The operative approach was divided into three categories: video-assisted thoracic surgery (VATS), robot-assisted thoracic surgery (RATS), and thoracotomy. The operative procedure was divided into eight categories: wedge resection, segmentectomy, lobectomy, sleeve lobectomy, lobectomy combined with segmentectomy, lobectomy combined with chest wall resection, bi-lobectomy, and pneumonectomy.

**Postoperative complications**

Postoperative complications were categorized into five grades according to the Clavien–Dindo classification system. Established in 1992, it is a simple and feasible grading system for all types of postoperative complications [18]. In 2004, it was modified to allow for the grading of life-threatening complications and long-term disability caused by a complication [19]. This revised version defined five grades of severity with subgrades (grades I, II, IIIa, IIIb, IVa, IVb, and V), and the suffix “d” (for “disability”) is used to denote any postoperative impairment. This modified version of the Clavien–Dindo classification has been widely used in clinical practice. Severe morbidity was defined according to the classification of RC-NCD, which was based on the STS GTSD risk model and included the following: respiratory failure, interstitial pneumonia, tracheobronchial fistula, pulmonary thromboembolism, pneumonia, redo surgery, myocardial infarction, arrhythmia requiring therapy, renal failure, postoperative bleeding, and chylothorax [12, 13].

(See figure on next page.)

**Fig. 1** Risk factors of the risk calculator of the national clinical database in Japan. BMI body mass index, PS performance status, VC vital capacity, %FEV₁ forced expiratory volume % in one second, Hb hemoglobin, BI Brinkman index, Chemo chemotherapy, Rad radiation, CRT chemoradiotherapy, CT computed tomography, SSIT superior sulcus tumor, Ao aorta, SVC supra vena cava, BCV brachiocephalic vein, PC pericardium, PA pulmonary artery, LA left atrium, D diaphragm, PP parietal pleura, CW chest wall, Vert vertebra, Es esophagus, Lob other pulmonary lobe, Seg segmentectomy, Wed wedge resection, Ad adenocarcinoma, Sq squamous cell carcinoma, Large large cell carcinoma, LCNEC large cell neuroendocrine carcinoma, SCLC small cell lung cancer, AdSq adenosquamous cell carcinoma, Pleo pleomorphic carcinoma, Carc carcinoid, Sal salivary gland cancer, UC unclassifiable cancer, SM simultaneous multiple cancer.
| Risk factor          | Description                                      |
|---------------------|--------------------------------------------------|
| Sex                 | Man / Woman                                      |
| Age                 |                                                  |
| BMI                 |                                                  |
| PS                  | 0 / 1 / 2 / 3 / 4 / unknown                      |
| %VC                 |                                                  |
| FVC                 |                                                  |
| %FEV$_{1.0}$        |                                                  |
| Comorbidity         | Liver cirrhosis (Child-Pugh class B/C)           |
|                     | Hemodialysis                                     |
|                     | Interstitial pneumonia                           |
|                     | Ischemic heart disease                           |
|                     | Malignant disease within 5 years                 |
|                     | Stroke or cranial nerve disease                  |
|                     | Diabetes mellitus                                |
|                     | Anemia (Hb $\leqslant$ 8.0g/dl)                  |
|                     | Autoimmune disease                               |
|                     | Arrhythmia                                       |
|                     | Hypertension                                     |
|                     | Others                                           |
| Smoking status      | Never / BI $<$200 / 200 $\leqslant$ BI $<$600 / 600 $\leqslant$ BI |
| Induction therapy   | Never / Chemo / Rad / CRT / Others               |
| Tumor diameter on CT|                                                  |
| cStage              |                                                  |
| Operative procedure | Right pneumonectomy                              |
|                     | Left pneumonectomy                               |
|                     | Bi-lobectomy                                     |
|                     | Right upper lobectomy                            |
|                     | Right lower lobectomy                            |
|                     | Lobectomy of other lobe                          |
|                     | Others                                           |
| SST                 | Absent / Present                                 |
| Node dissection     | 0 / 1a / 1b / 2a-1 / 2a-2 / 2b / 3a / 3β / 3γ / unknown |
| Combine resection   | Absent / Present                                 |
| Histology           | Ad/Sq/Large/LCNEC/SCLC/AdSqaPleo/Carc/Sal/UC/SM/Others |

**Fig. 1** (See legend on previous page.)
Furthermore, we added air leakage requiring therapy, atelectasis, asthma attacks, and cerebral infarction as postoperative morbidities.

### Statistical analyses

Pearson's chi-squared test of independence was used to compare the frequencies of the variables. Risk factors related to postoperative complications were analyzed using a logistic regression analysis. Factors showing significant differences in the univariate analysis were included in the multivariate analysis. All statistical analyses were two-sided, and statistical significance was set at $p < 0.05$. Statistical analyses were conducted using the JMP software program (version 13.2; SAS Institute Inc., Cary, NC, USA).

The present study was conducted in accordance with the principles of the Declaration of Helsinki. The Institutional Review Board of Kanazawa Medical University approved the protocol (approval number: I392), and written informed consent was obtained from all patients.

### Results

#### Patient characteristics, operative factors, postoperative morbidity, and mortality

The clinical characteristics of the 585 patients are shown in Table 1. Altogether, 333 patients had comorbidities, including 81 patients with the history of other malignant disease in addition to NSCLC (16 with colon cancer, 6 with rectal cancer, 14 with gastric cancer, 2 with esophageal cancer, 12 with breast cancer, 8 with prostate cancer, 9 with bladder cancer, 3 with gallbladder cancer, 7 with thyroid cancer, 3 with renal cancer, 4 with laryngeal cancer, 3 with pharyngeal cancer, and 5 with lymphoma; duplication occurred in some patients), 92 patients with hypertension, 81 with diabetes mellitus, 37 with angina pectoris, 35 with COPD, 24 with cerebral infarction, 20 with arrhythmia (18 with atrial fibrillation, 1 with paroxysmal supraventricular tachycardia, and 1 with atrioventricular block), 9 with interstitial lung disease, 20 with asthma, 15 with autoimmune disease, and 7 with chronic renal failure.

Postoperative morbidities were observed in 176 patients (30.0%). Clavien–Dindo grade 1 complication was noted in 1 patient, grade II in 71, grade IIIa in 99, and grade IIIb in 5. Air leakage occurred in 81 patients, arrhythmia in 44 (atrial fibrillation in 37, paroxysmal supraventricular tachycardia in 3, ventricular tachycardia in 3, and sick sinus syndrome in 1), atelectasis in 19, pneumonia in 12, asthma attacks in 4, cerebral infarction in 3, chylothorax in 2, and bronchopleural fistula in 2. Minor but serious postoperative complications included postoperative bleeding in one patient and right middle lobe torsion in another patient. All complications were resolved surgically.

Postoperative death was noted in 1 patient, and the mortality rate was 0.1%. Mortality and severe morbidities according to the RC-NCD were observed in 67 patients (11.4%); the severe morbidities were respiratory failure in 4 patients, tracheobronchial fistula in 2, pneumonia in 12, redo surgery in 2 (including postoperative bleeding in 1), arrhythmia requiring therapy in 44 (atrial fibrillation in 37, paroxysmal supraventricular tachycardia in 3, ventricular tachycardia in 3, and sick sinus syndrome in 1), and chylothorax in 2.

The median mortality rate according to the RC-NCD was 0.2%, the median mortality and severe morbidity rate was 4.6%, the median incidence rate of tracheal or bronchial fistula was 0.2%, and the median incidence rate of respiratory dysfunction was 0.2%.

#### Results of the univariate analysis

The relationships between patient characteristics or operative factors and postoperative morbidity or severe morbidity were analyzed (Table 2). Postoperative morbidities were more likely to be associated with the coexistence of COPD ($p = 0.03$), coexistence of asthma ($p < 0.01$), smoking status ($p < 0.01$), CEA ($p = 0.03$), NLR $>1.56$ ($p = 0.01$), FEV$_1$% $<70$ ($p < 0.01$), pulmonary lobe (right upper or right lower or left upper) ($p < 0.01$), squamous cell carcinoma ($p = 0.02$), and extend-lobectomy ($p = 0.02$) than other factors. Severe postoperative morbidity was more likely to be associated with low %VC ($p < 0.02$), squamous cell carcinoma ($p < 0.01$), and extend-lobectomy ($p = 0.01$) than other factors. Significant risk factors for other postoperative complications could not be assessed because of the small number of patients with these complications.

#### Results of the multivariate analysis

Multivariate analyses of the risk factors for postoperative morbidities are presented in Table 3. The coexistence of asthma (odds ratio [OR] 3.07, 95% confidence interval...
Table 1 Patient characteristics and perioperative data

| Variables | Sex (man / woman) | 364 / 221 | Age, median (y) | 69 (34–92) | Comorbidity | 333 (56.9%) | Malignant disease | 81 (13.8%) | Hypertension | 92 (15.7%) | Diabetes mellitus | 81 (13.8%) | Angina pectoris | 37 (6.3%) | COPD | 35 (5.9%) | Cerebral infarction | 24 (4.1%) | Arrhythmia | 20 (3.4%) | Interstitial lung disease | 9 (1.5%) | Asthma | 20 (3.4%) | Autoimmune disease | 15 (2.5%) | Chronic renal failure | 7 (1.1%) | Body mass index, median (range) | 22.8 (14.3–36.6) | CEA, median, range (ng/ml) | 3.4 (0.5–306) | Brinkman index, median (range) | 600 (0–3600) | PNI, median (range) | 50 (20.6–67.5) | NLR, median (range) | 2.14 (0.66–12.65) | %VC, median (range) | 111 (45.7–184.2) | FEV1%, median (range) | 75.4 (30.5–99.5) |
|-----------|------------------|----------|----------------|-------------|-------------|-------------|----------------|-------------|-------------|-------------|---------------|-------------|----------------|-------------|----------|---------------|-------------------|----------------|----------------|-------------------|----------------|----------------|-------------------|----------------|----------------|-------------------|
| Lobectomy | Lobe of lung cancer (RU / RM / RL / LU / LL) | 179 / 37 / 137 / 139 / 93 | Operative procedure (Seg / Lob / Lu / RM / RL / LU / LL) | 32 / 284 / 107 / 43 / 57 / 51 / 3 / 2 / 5 / 1 | Histological type (Ad / Sq / LCNEC / AdSq / Pleo / Large / Carci) | 441 / 108 / 17 / 9 / 4 / 3 / 3 | Operative approach (Open / VATS / RATS) | 71 / 662 / 6 | Location of Lobectomy (RU / RM / RL / LU / LL) | 175 / 36 / 106 / 108 / 76 | Operative procedure (Seg / Lob / Lu / RM / RL / LU / LL) | 68 / 473 / 9 / 3 / 4 / 10 / 18 | Morbidity | 176 (30.0%) | Air leakage | 81 (13.8%) | Arrhythmia | 44 (7.5%) | Atelectasis | 19 (3.2%) | Pneumonia | 12 (2.0%) | Attack of asthma | 4 (0.6%) | Cerebral infarction | 3 (0.5%) | Chylothorax | 2 (0.3%) | Broncho-pleural fistula | 2 (0.3%) | Clavien–Dindo grade (0 / I / II / IIIa / IIIb) | 409 / 1 / 71 / 99 / 5 | Mortality | 1 (0.1%) | Mortality or severe morbidity | 67 (11.4%) | Tracheal or bronchial fistula | 2 (0.3%) | Respiratory dysfunction | 4 (0.6%) | NCD risk score | Mortality, median (range) | 0.2 (0–10.6) | Mortality or severe morbidity, median (range) | 46 (1–39.3) | Tracheal or bronchial fistula, median (range) | 0.2 (0–8.1) | Respiratory dysfunction, median (range) | 0.2 (0–8.2) |

Table 1 (continued)

COPD chronic obstructive pulmonary disease, CEA carcinoembryonic antigen, PNI prognostic nutritional index, NLR neutrophil-to-lymphocyte ratio, VC vital capacity, FEV₁ forced expiratory volume in one second, RU right upper, RM right middle, RL right lower, LU left upper, LL left lower, p pathological, y yield to treatment, Ad adenocarcinoma, Sq squamous cell carcinoma, LCNEC large cell neuroendocrine carcinoma, AdSq adenosquamous cell carcinoma, Large large cell carcinoma, Carci carcinoid, Open open thoracotomy, VATS video-assisted thoracic surgery, RATS robotic-assisted thoracic surgery, RU right upper, RM right middle, RL right lower, LU left upper, LL left lower, RM right middle, RL right lower, LU left upper, LL left lower, Seg segmentectomy, Lob lobectomy, CW chest wall resection, Bilob bi-lobectomy, Pneumo pneumonectomy, NCD national clinical database

Results of the sub-analysis

We analyzed the risk factors for postoperative morbidity in patients who underwent lobectomy as a sub-analysis. The clinical characteristics of the 473 patients who underwent lobectomy are shown in Table 4. Among these, 163 underwent right upper lobectomy (RUL), 37 underwent right lower lobectomy (RLL), 94 underwent right middle lobectomy (RML), 94 underwent left upper lobectomy (LUL), and 74 underwent left lower lobectomy (LLL). Postoperative morbidities were observed in 142 patients (30.0%). A Clavien–Dindo grade I complication was noted in 1 patient, grade II in 54, grade IIIa in 83, and grade IIIb in 4. The mortality rate was 0. Mortality and severe morbidities according to the RC-NCD were observed in 52 patients (10.9%). The median mortality rate according to the RC-NCD was 0.2%, the median mortality and severe morbidity rate was 4.6%, the median incidence rate of tracheal or bronchial fistula was 0.2%, and the median incidence rate of respiratory dysfunction was 0.2%.

The comparison between the risk score according to the RC-NCD and postoperative morbidity by lobes is shown in Table 5. Although the risk scores for mortality or severe morbidity according to the RC-NCD were extremely high in RUL and RLL, the mortality and severe morbidity rates were not significantly different among lobes, although the morbidity rate tended to be high in RUL, RLL, and LUL.
| Variables | Morbidity | | | Severe morbidity | | |
| --- | --- | --- | --- | --- | --- |
| | Absent, n (%) | Present, n (%) | P value | Absent, n (%) | Present, n (%) | P value |
| Sex | Man | 254 (69.8) | 110 (30.2) | 0.92 | 317 (87.1) | 47 (12.9) | 0.15 |
| | Woman | 155 (70.1) | 66 (29.8) | 0.92 | 201 (90.9) | 20 (9.1) | 0.15 |
| Age | ≥ 75 | 304 (68.5) | 140 (31.5) | 0.17 | 391 (88.1) | 53 (11.9) | 0.51 |
| | < 75 | 304 (68.5) | 140 (31.5) | 0.17 | 391 (88.1) | 53 (11.9) | 0.51 |
| Comorbidity | Malignant disease | Absent | 347 (68.8) | 157 (31.2) | 0.16 | 444 (88.1) | 60 (11.9) | 0.39 |
| | | Present | 62 (76.5) | 19 (23.5) | 0.16 | 74 (91.4) | 7 (8.6) | 0.16 |
| | Angina pectoris | Absent | 386 (70.4) | 162 (29.6) | 0.28 | 484 (88.3) | 64 (11.7) | 0.50 |
| | | Present | 23 (62.2) | 14 (37.8) | 0.28 | 34 (91.9) | 3 (8.1) | 0.28 |
| | Cerebral infarction | Absent | 392 (69.9) | 169 (30.1) | 0.92 | 495 (88.2) | 66 (11.8) | 0.25 |
| | | Present | 17 (70.8) | 7 (29.2) | 0.92 | 23 (95.8) | 1 (4.2) | 0.92 |
| | Interstitial lung disease | Absent | 402 (69.8) | 174 (30.2) | 0.60 | 511 (88.7) | 65 (11.3) | 0.30 |
| | | Present | 7 (77.8) | 2 (22.2) | 0.60 | 7 (77.8) | 2 (22.2) | 0.60 |
| | Chronic renal failure | Absent | 406 (70.2) | 172 (29.8) | 0.11 | 512 (88.3) | 64 (11.7) | 0.81 |
| | | Present | 3 (42.8) | 45 (57.2) | 0.11 | 6 (85.7) | 1 (14.3) | 0.11 |
| | Diabetes mellitus | Absent | 355 (70.4) | 149 (29.6) | 0.49 | 446 (88.5) | 58 (11.5) | 0.91 |
| | | Present | 54 (66.7) | 27 (33.3) | 0.49 | 72 (88.9) | 9 (11.1) | 0.49 |
| | COPD | Absent | 390 (70.9) | 160 (29.1) | 0.03 | 490 (89.1) | 60 (10.9) | 0.10 |
| | | Present | 19 (54.3) | 16 (45.7) | 0.03 | 28 (80.0) | 7 (20.0) | 0.03 |
| | Asthma | Absent | 401 (71.0) | 164 (29.0) | < 0.01 | 504 (88.7) | 64 (11.3) | 0.61 |
| | | Present | 8 (40.0) | 12 (60.0) | < 0.01 | 17 (85.0) | 3 (15.0) | < 0.01 |
| | Arrhythmia | Absent | 395 (69.9) | 170 (30.1) | 0.99 | 500 (88.5) | 65 (11.5) | 0.83 |
| | | Present | 14 (70.0) | 6 (30.0) | 0.99 | 18 (90.0) | 2 (10.0) | 0.99 |
| | Autoimmune disease | Absent | 397 (69.6) | 173 (30.3) | 0.38 | 505 (88.6) | 65 (11.4) | 0.81 |
| | | Present | 12 (80.0) | 3 (20.0) | 0.38 | 13 (86.7) | 2 (13.3) | 0.38 |
| | Hypertension | Absent | 346 (69.8) | 149 (30.2) | 0.86 | 433 (87.8) | 60 (12.2) | 0.20 |
| | | Present | 65 (70.6) | 27 (29.3) | 0.86 | 85 (92.4) | 7 (7.6) | 0.86 |
| | Smoking status | Brinkman index < 600 | 223 (76.9) | 67 (23.1) | < 0.01 | 263 (90.7) | 27 (9.3) | 0.10 |
| | | Brinkman index ≥ 600 | 186 (63.1) | 109 (36.9) | < 0.01 | 255 (86.4) | 40 (13.6) | < 0.01 |
| | BMI | < 21.88 | 149 (67.1) | 73 (32.9) | 0.24 | 203 (91.4) | 19 (8.6) | 0.08 |
| | | ≥ 21.88 | 260 (71.6) | 103 (28.4) | 0.24 | 315 (86.8) | 48 (13.2) | 0.24 |
| | CEA | ≤ 5 | 299 (72.6) | 113 (27.4) | 0.03 | 367 (89.1) | 45 (10.9) | 0.53 |
| | | > 5 | 110 (63.6) | 63 (36.4) | 0.03 | 151 (87.3) | 22 (12.7) | 0.03 |
| | PNI | ≥ 49.68 | 228 (73.3) | 83 (26.7) | 0.05 | 282 (90.7) | 29 (9.3) | 0.08 |
| | | < 49.68 | 181 (66.1) | 93 (33.9) | 0.05 | 236 (86.1) | 38 (13.9) | 0.05 |
| | NLR | ≤ 1.56 | 108 (78.3) | 30 (21.7) | 0.01 | 124 (89.9) | 14 (10.1) | 0.58 |
| | | > 1.56 | 301 (67.3) | 146 (32.7) | 0.01 | 394 (88.1) | 53 (11.9) | 0.58 |
| | %VC | ≥ 80 | 402 (70.3) | 170 (29.7) | 0.20 | 510 (89.2) | 62 (10.8) | < 0.01 |
| | | < 80 | 7 (53.8) | 6 (46.2) | 0.20 | 8 (61.5) | 5 (38.5) | 0.20 |
| | FEV1% | ≥ 70 | 285 (75.4) | 93 (24.6) | < 0.01 | 341 (90.2) | 37 (9.8) | 0.08 |
| | | < 70 | 124 (59.9) | 83 (40.1) | < 0.01 | 177 (85.5) | 30 (14.5) | < 0.01 |
| Pulmonary lobe of NSCLC | RUL | 120 (67.0) | 59 (33.0) | 0.01 | 157 (87.7) | 22 (12.3) | 0.16 |
| | RLL | 31 (83.8) | 6 (16.2) | 0.01 | 34 (91.9) | 3 (8.1) | 0.01 |
| | LUL | 97 (70.8) | 40 (29.2) | 0.01 | 122 (89.1) | 15 (10.9) | 0.01 |
| | LLL | 87 (62.6) | 52 (37.4) | 0.01 | 117 (84.2) | 22 (15.8) | 0.01 |
| | RUL or RLL or LUL | 304 (66.8) | 151 (33.2) | < 0.01 | 396 (87.0) | 59 (13.0) | 0.03 |
| | RML or LLL | 105 (80.8) | 25 (19.2) | < 0.01 | 122 (93.9) | 8 (6.1) | < 0.01 |
The relationships between patient characteristics or operative factors and postoperative morbidity or severe morbidity for patients who underwent lobectomy were analyzed (Table 6). Postoperative morbidities tended to be associated with the coexistence of chronic renal failure (p = 0.04), coexistence of asthma (p < 0.04), smoking status (p < 0.01), CEA (p = 0.04), NLR > 1.56 (p = 0.01), FEV1% < 70 (p < 0.01), and RUL, RLL, or LUL (p < 0.01). Severe postoperative morbidity tended to be associated with male sex (p = 0.01), a high BMI (p < 0.01), low %VC (p < 0.02), squamous cell carcinoma (p = 0.04), and RUL, RLL, or LUL (p = 0.03).
Multivariate analyses of risk factors for postoperative morbidity and severe morbidity for patients who underwent lobectomy are shown in Table 7. The coexistence of asthma (OR 4.18, 95% CI 1.291–13.556, p = 0.01) and the performance of RUL, RLL, or LUL (OR 2.21, 95% CI 1.277–3.823, p < 0.01) were identified as significant risk factors for postoperative morbidity, while male sex (OR 2.35, 95% CI 1.152–4.818, p = 0.01), a high BMI (OR 2.41, 95% CI 1.034–16.174, p = 0.04), and performance of RUL, RLL, or LUL (OR 2.65, 95% CI 1.083–6.495, p = 0.03) were identified as significant risk factors for severe postoperative morbidity.

**Discussion**

In the present study, we analyzed the risk factors for postoperative morbidity in patients who underwent pulmonary resection for NSCLC. Several factors, such as the age, comorbidity, smoking history, operative approach, and type of operative procedure, have been reported as risk factors for postoperative morbidity in NSCLC patients who have undergone pulmonary resection [5, 7, 8, 13, 20, 21]. The sex, coexistence of asthma, FEV1%, and type of operative procedure were shown to be significant risk factors for postoperative morbidity in a previous study [22]; in the present study as well, the coexistence of asthma, NLR, and pulmonary lobe were significant risk factors for postoperative morbidity, whereas the %VC, pulmonary lobe and type of operative procedure were significant risk factors for severe postoperative morbidity.

RUL has been reported to be a significant risk factor for severe postoperative morbidity in the Japanese nationwide database [12]. Although the risk factors for postoperative morbidity might vary depending on the number of patients or patient characteristics, the type of operative procedure is likely to be a significant risk factor for postoperative morbidity in patients who have undergone pulmonary resection. In the present study, the mortality and severe morbidity rates were not significantly different among lobes, whereas the morbidity rate tended to be high in RUL, RLL, and LUL. Furthermore, the operative approach, and type of operative procedure, have been reported as risk factors for postoperative morbidity in NSCLC patients who have undergone pulmonary resection [5, 7, 8, 13, 20, 21]. The sex, coexistence of asthma, FEV1%, and type of operative procedure were shown to be significant risk factors for postoperative morbidity in a previous study [22]; in the present study as well, the coexistence of asthma, NLR, and pulmonary lobe were significant risk factors for postoperative morbidity, whereas the %VC, pulmonary lobe and type of operative procedure were significant risk factors for severe postoperative morbidity.

RUL has been reported to be a significant risk factor for severe postoperative morbidity in the Japanese nationwide database [12]. Although the risk factors for postoperative morbidity might vary depending on the number of patients or patient characteristics, the type of operative procedure is likely to be a significant risk factor for postoperative morbidity in patients who have undergone pulmonary resection. In the present study, the mortality and severe morbidity rates were not significantly different among lobes, whereas the morbidity rate tended to be high in RUL, RLL, and LUL. Furthermore, the operative approach, and type of operative procedure, have been reported as risk factors for postoperative morbidity in NSCLC patients who have undergone pulmonary resection [5, 7, 8, 13, 20, 21]. The sex, coexistence of asthma, FEV1%, and type of operative procedure were shown to be significant risk factors for postoperative morbidity in a previous study [22]; in the present study as well, the coexistence of asthma, NLR, and pulmonary lobe were significant risk factors for postoperative morbidity, whereas the %VC, pulmonary lobe and type of operative procedure were significant risk factors for severe postoperative morbidity.

| Variables                        | Values                  |
|----------------------------------|-------------------------|
| Sex (man / woman)               | 303 / 170               |
| Age, median, range (y)          | 69 (34–92)              |
| Comorbidity                      | 232 (53.1%)             |
| Malignant disease                | 58 (12.2%)              |
| Hypertension                     | 73 (15.4%)              |
| Diabetes mellitus                | 71 (15.0%)              |
| Angina pectoris                  | 32 (6.8%)               |
| COPD                             | 29 (6.1%)               |
| Cerebral infarction              | 20 (4.2%)               |
| Arrhythmia                       | 16 (3.4%)               |
| Interstitial lung disease        | 7 (1.5%)                |
| Asthma                           | 14 (2.9%)               |
| Autoimmune disease               | 11 (2.3%)               |
| Chronic renal failure            | 6 (1.2%)                |
| Body mass index, median (range)  | 22.9 (14.3–36.6)        |
| CEA, median, range (ng/ml)       | 3.4 (0.5–269)           |
| Brinkman index, median (range)   | 600 (0–3600)            |
| PNI, median (range)              | 50.1 (31.8–64.2)        |
| NLR, median (range)              | 2.07 (0.77–12.65)       |
| %VC, median (range)              | 111.2 (45.7–184.2)      |
| FEV1%, median (range)            | 73.8 (30.5–99.5)        |
| pStage (I / IA / IB / IIA / IIB / IIA / IIB / IV / yIA) | 48 / 419 / 6 |
| Histological type (Ad / Sq / LCNEC / AdSq / Pleo / Large / Carci) | 362 / 81 / 14 / 8 / 2 / 3 / 3 |
| Operative approach (Open / VATS / RATS) | 48 / 419 / 6 |
| Operative procedure              |                         |
| RUL                              | 163 (34.5%)             |
| RML                              | 37 (7.8%)               |
| RLL                              | 94 (19.8%)              |
| LUL                              | 105 (22.9%)             |
| LLL                              | 74 (15.6%)              |
| Morbidity                        | 142 (30.0%)             |
| Air leakage                      | 67 (14.1%)              |
| Arrhythmia                       | 35 (7.4%)               |
| Atelectasis                      | 16 (3.4%)               |
| Pneumonia                        | 8 (1.7%)                |
| Attack of asthma                 | 3 (0.6%)                |
| Cerebral infarction              | 3 (0.6%)                |
| Chylothorax                      | 2 (0.4%)                |
| Broncho-pleural fistula          | 1 (0.2%)                |
| Clavien–Dindo grade (0 / 1 / 2 / 3a / 3b) | 331 / 1 / 54 / 83 / 4 |
| Mortality                        | 0 (0%)                  |
| Mortality or severe morbidity    | 52 (10.9%)              |
| Tracheal or bronchial fistula    | 1 (0.2%)                |
| Respiratory dysfunction          | 4 (0.8%)                |
| NCD risk score                   |                         |
| Mortality, median (range) (%)    | 0.2 (0–10.3)            |
| Mortality or severe morbidity, median (range) (%) | 4.6 (1.2–27.3) |
| Tracheal or bronchial fistula, median (range) (%) | 0.2 (0–3.4) |
| Respiratory dysfunction, median (range) (%) | 0.2 (0–4.4) |
procedure, including RUL, RLL, and LUL, was a significant risk factor for severe postoperative morbidity in the multivariate analysis. Therefore, we considered that the RC-NCD for postoperative severe morbidity should need to be modified according to high-risk lobes.

In the present study, postoperative morbidity for patients who underwent lobectomy was significantly related to the coexistence of asthma and the type of operative procedure, specifically RUL, RLL, or LUL. Although air leakage requiring therapy, atelectasis, asthma attacks, and cerebral infarction are not considered severe postoperative morbidities by the RC-NCD, they are important complications after pulmonary resection. In a previous study, the sex and operative approach, including VATS and RATS, were identified as significant risk factors for postoperative air leakage, while the coexistence of asthma was a significant risk factor for postoperative atelectasis [22]. Cerebral infarction after pulmonary resection is a rare but unfortunate complication, and one risk factor that has been analyzed and reported was the performance of LUL [23]. Cerebral infarction is considered to increase due to blood clots in pulmonary vein stump. Because cerebral infarction is rare but an important postoperative complication, the risk analysis for postoperative cerebral infarction should be done separately in RC-NCD. On the other hand, air leakage was most morbidity in the present study. Furthermore, atelectasis and attack of asthma was rare but the important morbidities. Therefore, air leakage requiring therapy, atelectasis, and asthma attacks should be included as important postoperative morbidities in the RC-NCD. Furthermore, the risk factors related to these important postoperative morbidities after pulmonary resection should be analyzed using a large-scale survey in the future.

Several limitations associated with the present study warrant mention. For example, this study had a retrospective design, patients’ performance status wasn’t analyzed, and there was a possibility of unobserved confounding and selection bias. In addition, the present study was performed at a single institution.

### Conclusions

We analyzed the risk factors for postoperative morbidity in patients who underwent pulmonary resection. The coexistence of asthma, NLR, and pulmonary lobe were significant risk factors for postoperative morbidity in the present study, and the %VC, pulmonary lobe, and type of operative procedure were significant risk factors for severe postoperative morbidity. Furthermore, in patients received lobectomy, coexistence of asthma and pulmonary lobe were identified as significant risk factors for postoperative morbidity. Meanwhile, male sex, high BMI, low VC, and pulmonary lobe were identified as significant risk factors for severe postoperative morbidity. Given that the pulmonary lobe was a significant risk factor for postoperative morbidity in patients received pulmonary resection and for severe postoperative morbidity in patients received lobectomy, the RC-NCD for postoperative morbidity needs to be modified according to high-risk lobes.

### Table 5 Comparison between risk score according to RC-NCD and postoperative morbidity by lobes

| Procedure | RUL  | RML  | RLL  | LUL  | LLL  | P value |
|-----------|------|------|------|------|------|---------|
| NCD risk score |      |      |      |      |      |         |
| Mortality, median (range) (%) | 0.3 (0–2.5) | 0.1 (0–1.1) | 0.4 (0–10.3) | 0.1 (0–2.4) | 0.1 (0–4.3) | <0.01 |
| Mortality or severe morbidity, median (range) (%) | 5.7 (1.8–19.7) | 2.6 (1.2–12.2) | 5.3 (1.8–27.3) | 3.7 (1.2–21.6) | 2.9 (1.2–16.5) | <0.01 |
| Tracheal or bronchial fistula, median (range) (%) | 0.2 (0–0.6) | 0.1 (0–0.8) | 0.6 (0–1–3.4) | 0.2 (0–0.6) | 0.1 (0–1.1) | <0.01 |
| Respiratory dysfunction, median (range) (%) | 0.2 (0–1.4) | 0.1 (0–0.7) | 0.2 (0–2.5) | 0.2 (0–2.5) | 0.1 (0–4.4) | <0.01 |
| Clinical data |      |      |      |      |      |         |
| Mortality or severe morbidity (%) | 11.6 | 8.1 | 9.6 | 17.1 | 4.1 | 0.08 |
| Tracheal or bronchial fistula (%) | 0 | 0 | 0 | 0.9 | 0 | 0.47 |
| Respiratory dysfunction (%) | 0.6 | 0 | 1.1 | 1.9 | 0 | 0.64 |
| Morbidity (%) | 32.5 | 16.2 | 32.9 | 35.2 | 20.3 | 0.06 |
| Air leakage (%) | 14.7 | 5.4 | 18.1 | 14.3 | 12.1 | 0.43 |
| Arrhythmia (%) | 7.9 | 8.1 | 5.3 | 11.4 | 2.7 | 0.23 |
| Pneumonia (%) | 1.2 | 0 | 2.1 | 2.8 | 1.3 | 0.76 |
| Atelectasis (%) | 4.9 | 2.7 | 3.2 | 1.9 | 2.7 | 0.73 |

RC-NCD risk calculator of national clinical database, RUL right upper lobectomy, RML right middle lobectomy, RLL right lower lobectomy, LUL left upper lobectomy, LLL left lower lobectomy
### Table 6  Univariate analysis of risk factors for postoperative morbidity and severe morbidity in patients received lobectomy

| Variables                        | Morbidity | P value | Severe morbidity | P value |
|----------------------------------|-----------|---------|------------------|---------|
|                                  | Absent, n (%) | Present, n (%) | Absent, n (%) | Present, n (%) |
| Sex                              | Man       | 209 (68.9) | 94 (31.1) | 0.52 | 262 (86.5) | 41 (13.5) | 0.01 |
|                                  | Woman     | 122 (71.8) | 48 (28.2) | 0.49 | 159 (93.5) | 11 (6.5) | 0.90 |
| Age                              | ≥ 75      | 77 (72.6) | 29 (27.4) |       | 94 (88.7) | 12 (11.3) |       |
|                                  | < 75      | 254 (69.2) | 113 (30.8) | 0.61 | 327 (89.1) | 40 (10.9) |       |
| Comorbidity                      |           |          |                 |       |           |          |       |
| Malignant disease                | Absent    | 288 (69.4) | 127 (30.6) | 0.46 | 369 (88.9) | 46 (11.1) | 0.86 |
|                                  | Present   | 43 (74.1) | 15 (25.9) |       | 52 (89.7) | 6 (10.3) |       |
| Angina pectoris                  | Absent    | 311 (70.5) | 130 (29.5) | 0.33 | 392 (88.9) | 49 (11.1) | 0.76 |
|                                  | Present   | 20 (62.5) | 12 (37.5) |       | 29 (90.6) | 3 (9.4) |       |
| Cerebral infarction              | Absent    | 318 (70.2) | 135 (29.8) | 0.61 | 402 (88.7) | 51 (11.3) | 0.38 |
|                                  | Present   | 13 (65.0) | 7 (35.0) |       | 19 (95.0) | 1 (5.0) |       |
| Interstitial lung disease        | Absent    | 325 (69.7) | 141 (30.3) | 0.36 | 415 (89.1) | 51 (10.9) | 0.77 |
|                                  | Present   | 6 (85.7) | 1 (14.3) |       | 6 (85.7) | 1 (14.3) |       |
| Chronic renal failure            | Absent    | 329 (70.5) | 138 (29.5) | 0.04 | 416 (89.1) | 51 (10.9) | 0.65 |
|                                  | Present   | 2 (33.3) | 4 (66.7) |       | 5 (83.3) | 1 (16.7) |       |
| Diabetes mellitus                | Absent    | 284 (70.7) | 118 (29.3) | 0.45 | 358 (89.1) | 44 (10.1) | 0.93 |
|                                  | Present   | 47 (66.2) | 24 (33.8) |       | 63 (88.7) | 8 (11.3) |       |
| COPD                             | Absent    | 315 (70.9) | 129 (29.1) | 0.07 | 398 (89.6) | 46 (10.4) | 0.08 |
|                                  | Present   | 16 (55.0) | 13 (44.8) |       | 23 (79.3) | 6 (20.7) |       |
| Asthma                           | Absent    | 326 (71.0) | 133 (29.0) | < 0.01 | 410 (89.3) | 49 (10.7) | 0.20 |
|                                  | Present   | 5 (35.7) | 9 (64.3) |       | 11 (78.6) | 3 (21.3) |       |
| Arrhythmia                       | Absent    | 321 (70.2) | 136 (29.8) | 0.50 | 407 (89.6) | 50 (10.9) | 0.84 |
|                                  | Present   | 10 (62.5) | 6 (37.5) |       | 14 (87.5) | 2 (12.5) |       |
| Autoimmune disease               | Absent    | 323 (69.9) | 139 (30.1) | 0.84 | 412 (89.2) | 50 (10.8) | 0.44 |
|                                  | Present   | 8 (72.7) | 3 (27.3) |       | 9 (81.8) | 2 (18.2) |       |
| Hypertension                     | Absent    | 279 (69.7) | 121 (30.3) | 0.79 | 354 (88.5) | 46 (11.5) | 0.40 |
|                                  | Present   | 52 (71.2) | 21 (28.8) |       | 67 (91.8) | 6 (8.2) |       |
| Smoking status                   | Brinkman index < 600 | 180 (76.3) | 56 (23.7) | < 0.01 | 213 (90.3) | 23 (9.7) | 0.38 |
|                                  | Brinkman index ≥ 600 | 151 (63.7) | 86 (36.3) |       | 208 (87.8) | 29 (12.2) |       |
| BMI                              | < 22.93   | 165 (70.8) | 68 (29.2) | 0.69 | 217 (93.2) | 16 (6.8) | < 0.01 |
|                                  | ≥ 22.93   | 166 (69.2) | 74 (30.8) |       | 204 (85.0) | 36 (15.0) |       |
| CEA                              | ≤ 5       | 240 (72.7) | 90 (27.3) | 0.04 | 297 (90.0) | 33 (10.0) | 0.29 |
|                                  | > 5       | 91 (63.6) | 52 (36.4) |       | 124 (86.7) | 19 (13.3) |       |
| PNI                              | ≥ 49.68   | 190 (73.9) | 67 (26.1) | 0.04 | 234 (91.1) | 23 (8.9) | 0.12 |
|                                  | < 49.68   | 141 (65.3) | 75 (34.7) |       | 187 (86.6) | 29 (13.4) |       |
| NLR                              | ≤ 1.56    | 97 (78.2) | 27 (21.8) | 0.01 | 111 (89.5) | 13 (10.5) | 0.83 |
|                                  | > 1.56    | 234 (67.1) | 115 (32.9) | 0.25 | 414 (89.6) | 48 (10.4) | < 0.01 |
| %VC                              | ≥ 80      | 325 (70.4) | 137 (29.6) |       | 414 (89.6) | 48 (10.4) | < 0.01 |
|                                  | < 80      | 6 (54.6) | 5 (45.4) |       | 7 (63.6) | 4 (36.4) |       |
| FEV1%                            | ≥ 70      | 231 (74.3) | 80 (25.7) | < 0.01 | 281 (90.4) | 30 (9.6) | 0.19 |
|                                  | < 70      | 100 (61.7) | 62 (38.3) |       | 140 (86.4) | 22 (13.6) |       |
| Histological type                | Non-Squamous cell carcinoma | 279 (71.2) | 113 (28.8) | 0.21 | 354 (90.3) | 38 (9.7) | 0.04 |
|                                  | Squamous cell carcinoma | 52 (64.2) | 29 (35.8) |       | 67 (82.7) | 14 (17.3) |       |
| Operative approach               | VATS or RATS | 295 (69.4) | 130 (30.6) | 0.42 | 380 (89.4) | 45 (10.6) | 0.40 |
|                                  | Open thoracotomy | 36 (75.0) | 12 (25.0) |       | 41 (85.4) | 7 (14.6) |       |
| Operative procedure              | RML or LLL | 90 (81.1) | 21 (18.9) | < 0.01 | 105 (94.6) | 6 (5.4) | 0.03 |
|                                  | RUL or RLL or LUL | 241 (66.6) | 121 (33.4) | 0.34 | 316 (87.3) | 42 (12.7) |       |

COPD chronic obstructive pulmonary disease, CEA carcinoembryonic antigen, PNI prognostic nutritional index, NLR neutrophil-to-lymphocyte ratio, VC vital capacity, FEV1% forced expiratory volume % in one second, VATS video-assisted thoracic surgery, RATS robotic-assisted thoracic surgery, RML right middle lobectomy, LLL left lower lobectomy, RUL right upper lobectomy, RLL right lower lobectomy, LUL left upper lobectomy
Abbreviations
NSCLC: Non-small cell lung cancer; COPD: Chronic obstructive pulmonary disease; RC-NCD: Risk calculator of national clinical database; BMI: Body mass index; CEA: Carcinoembryonic antigen; PNI: Prognostic nutritional index; NLR: Neutrophil-to-lymphocyte ratio; CT: Computed tomography; VC: Vital capacity; FEV1%: Forced expiratory volume % in one second; VATS: Video-assisted thoracic surgery; RATS: Robotic-assisted thoracic surgery; OR: Odds ratio; CI: Confidence interval; RUL: Right upper lobectomy; RML: Right middle lobectomy; RLL: Right lower lobectomy; LUL: Left upper lobectomy; LLL: Left lower lobectomy.

Acknowledgements
Not applicable.

Author contributions
N. M. performed the research, collected and analyzed the data and wrote the paper. M.I., S. I., A.Y., and Y.I. contributed to sample collection. H. U. contributed to supervision of this study and revision of the manuscript. All authors have read and approved the final manuscript.

Funding
This study has not been funded.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to (our institutional restrictions e.g., them containing information that could compromise research participant privacy/consent), but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The present study was conducted in accordance with the amended Declaration of Helsinki. The Institutional Review Boards of Kanazawa Medical University approved the protocol (approval number:1392), and written informed consent was obtained from all of the patients.

Consent for publication
Not applicable.

Table 7  Multivariate analysis of risk factors for postoperative morbidity and severe morbidity in patients received lobectomy

| Variables                                      | Odds ratio | 95% CI       | P value |
|------------------------------------------------|------------|--------------|---------|
| Postoperative morbidity                        |            |              |         |
| Comorbidity                                    |            |              |         |
| Chronic renal failure                          | 4.82       | 0.809–28.755 | 0.08    |
| Asthma                                         | 4.18       | 1.291–15.556 | 0.01    |
| Smoking status                                 |            |              |         |
| Brinkman index ≥ 600                          | 1.45       | 0.930–2.266  | 0.10    |
| CEA                                            | 1.37       | 0.878–2.156  | 0.16    |
| PNI                                            | 1.40       | 0.921–2.130  | 0.11    |
| NLR                                            | 1.49       | 0.903–2.477  | 0.11    |
| FEV1%                                          | 1.30       | 0.828–2.051  | 0.25    |
| Operative procedure                            |            |              |         |
| RUL or RLL or LUL                             | 2.21       | 1.277–3.823  | <0.01   |
| Postoperative severe morbidity                 |            |              |         |
| Sex                                            | 2.35       | 1.152–4.818  | 0.01    |
| BMI                                            | 2.41       | 1.277–4.550  | <0.01   |
| %VC                                           | 4.09       | 1.034–16.174 | 0.04    |
| Histology                                      | 1.66       | 0.819–3.368  | 0.15    |
| Operative procedure                            | 2.65       | 1.083–6.495  | 0.03    |

CEA carcinoembryonic antigen, PNI prognostic nutritional index, NLR neutrophil-to-lymphocyte ratio, FEV1% forced expiratory volume % in one second, RUL right upper lobectomy, RLL right lower lobectomy, LUL left upper lobectomy, RUL right upper lobectomy, RML right middle lobectomy, RLL Right lower lobectomy, LUL Left upper lobectomy, LLL Left lower lobectomy.

Competing interests
The authors declare that they have no competing interests.

References
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
2. Rueth NM, Andrade RS. IS VATS lobectomy better: perioperatively, biologically and oncologically? Ann Thorac Surg. 2010;89:S2107–11.
3. Boffa DJ, Allen MS, Grab JD, Gaissert HA, Harpole DH, Wright CD. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg. 2008;135:247–54.
4. Allen MS, Darling GE, Pechet TTV, Mitchell JD, Herndon JE II, Landreneau RJ, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81:1013–20.
5. Berry MF, Hanna J, Tong BC, Burfeind WR, Harpole DH, D’Amico TA, et al. Risk factors for morbidity after lobectomy for lung cancer in elderly patients. Ann Thorac Surg. 2009;88:1093–9.
6. Jung R, He S, Dai H, Lin F, Ge W, Tao G, et al. Incidence and risk factors of postoperative pulmonary complications after thoracic surgery for early non-small cell lung cancer. Int J Clin Exp Med. 2018;11(1):285–94.
7. Agostini P, Cieslik H, Rathinam S, Bishay E, Kalkat MS, Rajesh PB, et al. Postoperative pulmonary complications following thoracic surgery: are there any modifiable risk factors? Thorax. 2010;65:815–8.
8. Stolz AJ, Schutzner J, Lischke R, Simonek J, Hanustik T, Paiko P. Predictors of atelectasis after pulmonary lobectomy. Surg Today. 2008;38:987–92.
10. Miyata H, Gotoh M, Hashimoto H, Motomura N, Murakami A, Tomotaki A, et al. Challenges and prospects of a clinical database linked to the board certification system. Surg Today. 2014;44:1991–9.
11. Endo S, Ikeda N, Kondo T, Nakajima J, Kono H, Yokoi K, et al. Model of lung cancer surgery risk derived from a Japanese nationwide web-based database of 78594 patients during 2014–2015. Eur J Cardiothorac Surg. 2017;52:1182–9.
12. Kozower BD, Sheng S, O'Brien SM, Liptay MJ, Lau CL, Jones DR, et al. STS Database risk models: predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg. 2010;90:875–83.
13. Fernandez FG, Kosinski AS, Burfeind W, Park B, DeCamp MM, Seder C, et al. The Society of Thoracic Surgeons lung cancer resection risk model: higher quality data and superior outcomes. Ann Thorac Surg. 2016;102:370–7.
14. Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato E. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980;139:160–7.
15. Zahorec R. Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5–14.
16. Brinkman GL, Coates EO. The effect of bronchitis, smoking, and occupation on ventilation. Am Rev Respir Dis. 1963;87:684–93.
17. Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111:518–26.
18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
19. Pei G, Zhou S, Han Y, Liu Z, Xu S. Risk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China. J Thorac Cardiovasc Surg. 2016;152:1230–8.
20. Yang R, Wu Y, Yao L, Xu J, Zhang S, Du C, et al. Risk factors of postoperative pulmonary complications after minimally invasive anatomic resection for lung cancer. Thorac Cancer. 2020;11:223–31.
21. Motono N, Ishikawa M, Iwai S, Iijima Y, Usuda K, Uramoto H. Individualization of risk factors for postoperative complication after lung cancer surgery: a retrospective study. BMC Surg. 2021;21:311.
22. Matsumoto K, Sato S, Okumura M, Niwa H, Hida Y, Kaga K, et al. Left upper lobectomy is a risk factor for cerebral infarction after pulmonary resection: a multicenter, retrospective, case-control study in Japan. Surg Today. 2020;50:1383–92.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.